Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK cells and monoclonal antibodies in R/R AML
NCT04662788Phase 1Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- Jan 2021
- Primary completion
- Jan 2024
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of NK cell therapy (Anhui Provincial Hospital) in acute myeloid leukemia (AML), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
NK cell therapy (Anhui Provincial Hospital)
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04662788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662788.